NCT05822544View on ClinicalTrials.gov

Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without Diabetes

PHASE1RecruitingINTERVENTIONAL
Enrollment

564

Participants

Timeline

Start Date

April 22, 2023

Primary Completion Date

October 31, 2025

Study Completion Date

December 31, 2025

Conditions
Healthy SubjectsObesityType 2 Diabetes
Interventions
DRUG

TLC-6740 Oral Solution

Oral solution of TLC-6740

OTHER

Placebo Oral Solution

Placebo-to-match oral solution TLC-6740

DRUG

TLC-6740 Tablet

Tablet formulation of TLC-6740

DRUG

Drug Metabolizing Enzyme

Oral dose of omeprazole, voriconazole, itraconazole, or rifampicin

DRUG

Tirzepatide

Subcutaneous injection of tirzepatide

OTHER

Placebo Tablet

Placebo-to-match tablet formulation of TLC-6740

Trial Locations (3)

Unknown

RECRUITING

OrsoBio Reseach Site, Auckland

RECRUITING

OrsoBio Research Site, Auckland

RECRUITING

OrsoBio Research Site, Christchurch

Sponsors

Lead Sponsor

OrsoBio, Inc
All Listed Sponsors
lead

OrsoBio, Inc

INDUSTRY

NCT05822544 - Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without Diabetes | Biotech Hunter | Biotech Hunter